Browse CHRM4

Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.

> Gene Ontology
 
Biological Process GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007197 adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007207 phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway
GO:0007213 G-protein coupled acetylcholine receptor signaling pathway
GO:0007271 synaptic transmission, cholinergic
GO:0060359 response to ammonium ion
GO:0071242 cellular response to ammonium ion
GO:0095500 acetylcholine receptor signaling pathway
GO:1903831 signal transduction involved in cellular response to ammonium ion
GO:1905144 response to acetylcholine
GO:1905145 cellular response to acetylcholine
Molecular Function GO:0008227 G-protein coupled amine receptor activity
GO:0015464 acetylcholine receptor activity
GO:0016907 G-protein coupled acetylcholine receptor activity
GO:0030594 neurotransmitter receptor activity
GO:0099528 G-protein coupled neurotransmitter receptor activity
Cellular Component GO:0045211 postsynaptic membrane
GO:0097060 synaptic membrane
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04725 Cholinergic synapse
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-375280: Amine ligand-binding receptors
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-390648: Muscarinic acetylcholine receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CHRM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CHRM4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CHRM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4440.612
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5840.208
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4710.488
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.3780.00935
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.9130.162
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7280.607
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4890.427
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.7210.381
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4280.0445
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CHRM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHRM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHRM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHRM4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHRM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CHRM4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CHRM4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCHRM4
Namecholinergic receptor, muscarinic 4
Aliases acetylcholine receptor, muscarinic 4; HM4; M4R; Muscarinic acetylcholine receptor M4
Chromosomal Location11p12-p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CHRM4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CHRM4.
ID Name Drug Type Targets #Targets
DB00246ZiprasidoneSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4 ......25
DB00321AmitriptylineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, ......35
DB00334OlanzapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1 ......50
DB00340MetixeneSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB00342TerfenadineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH27
DB00363ClozapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, ......27
DB00376TrihexyphenidylSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB00387ProcyclidineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB00408LoxapineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3 ......34
DB00411CarbacholSmall MoleculeACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRNA26
DB00420PromazineSmall MoleculeADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, D ......14
DB00424HyoscyamineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB00454PethidineSmall MoleculeCES1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, GRIN1, GRIN2A, GRIN2B, GR ......16
DB00458ImipramineSmall MoleculeADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, D ......25
DB00496DarifenacinSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB00540NortriptylineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB ......24
DB00543AmoxapineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2A, ADRA2B, ADRA2C, CH ......48
DB00555LamotrigineSmall MoleculeADORA1, ADORA2A, ADRA1A, ADRA2A, ADRB1, CACNA1E, CHRM1, CHRM2, CHR ......44
DB00568CinnarizineSmall MoleculeCACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CHR ......16
DB00572AtropineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA4, CHRNB2, GLRA18
DB00622NicardipineSmall MoleculeADRA1A, ADRA1B, ADRA1D, CACNA1C, CACNA1D, CACNA2D1, CACNB2, CHRM1, ......14
DB00715ParoxetineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A48
DB00725Homatropine MethylbromideSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB00726TrimipramineSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, ......24
DB00747ScopolamineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA4, CHRNB2, SI8
DB00767BenzquinamideSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH16
DB00777PropiomazineSmall MoleculeADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, D ......14
DB00785CryptenamineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB00809TropicamideSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB00835BrompheniramineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH16
DB00934MaprotilineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......17
DB01019BethanecholSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB01036TolterodineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB01069PromethazineSmall MoleculeADRA1A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HRH2, HTR2A10
DB01085PilocarpineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB01142DoxepinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......23
DB01151DesipramineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM ......21
DB01221KetamineSmall MoleculeBCHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, GRIN3A, HTR1A, HTR1 ......23
DB01224QuetiapineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......26
DB01238AripiprazoleSmall MoleculeADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4 ......25
DB01239ChlorprothixeneSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, ......12
DB01403MethotrimeprazineSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......19
DB01409TiotropiumSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB01591SolifenacinSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB01625IsopropamideSmall MoleculeCHRM3, CHRM42
DB03128AcetylcholineSmall MoleculeACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRNA76
DB05752ALKS 27Small MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB06702FesoterodineSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB06787HexocycliumSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM44
DB08897AclidiniumSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB09076UmeclidiniumSmall MoleculeCHRM1, CHRM2, CHRM3, CHRM4, CHRM55
DB09167DosulepinSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......16
DB09194EtoperidoneSmall MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM ......15